nucresiran

all catalysts(0)

nothing on the calendar yet

News(8)

• ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
  At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.
  biopharma_dive · 1mo ago
• ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
  As AstraZeneca appears to close the book on a combo approach following the phase 3 failure of its Ionis-partnered Wainua, several analysts contend it’s too early to count out Alnylam’s silencing dr…
  fiercebiotech · 1mo ago
• STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
  An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.
  stat · 1mo ago
• ‘Worse than expected’ Wainua data muddies water for TTR silencers
  AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined with the…
  biospace · 1mo ago
• AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
  Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
  biopharma_dive · 1mo ago
• What’s in Merck and Moderna’s cancer vaccine algorithm?
  A heart drug failure, RevMed's pancreatic cancer drug approved, and more biotech news from The Readout
  stat · 1mo ago
• 5 companies advancing ATTR assets in the wake of Wainua’s fail
  The Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals’ antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling—and readjusting. BioSpace looks at five con…
  biospace · 2mo ago
• Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
  Alnylam’s revenue cut “may create a near term credibility overhang and could “raise questions on peak sales potential, even if there’s tailwinds in the competitive landscape,” according to Stifel.
  biospace · 2mo ago